Mitochondria are essential organelles that not only generate the chemical energy required for cellular function but also regulate critical processes such as cell death and immunity. However, dysfunctional mitochondria can contribute to organismal aging and various diseases, including cancer and neurodegenerative conditions. This underscores the necessity of maintaining mitochondrial health for cellular homeostasis. Mitophagy, the selective degradation of dysfunctional mitochondria via lysosomes, is a key cellular strategy for preserving mitochondrial quality. Among the various mitophagy pathways, the PINK1/Parkin pathway has garnered significant attention due to its link to familial early-onset Parkinson’s disease (PD). In this process, PINK1/Parkin facilitate the formation of autophagosomes that encapsulate damaged mitochondria and deliver them to lysosomes for degradation.
My research has provided critical insights into the molecular mechanisms governing PINK1/Parkin mitophagy. Recently, we discovered that the PINK1/Parkin mitophagy can be initiated via two distinct branches, rather than one universal mechanism as previously thought (Nguyen et al. Mol Cell 2023; Adriaenssens*, Nguyen* et al. NSMB 2024; *co-first). This highlights the mechanistic plasticity of selective autophagy pathways, demonstrating that within the same type of selective autophagy, multiple initiation mechanisms can exist depending on the available autophagy adaptors, which may vary across different cell types and tissues. Additionally, we identified a novel role of TBK1 as an initiating kinase that activates the PI3K complex. Despite its essential role in autophagy, the molecular mechanisms underlying PI3K complex regulation and activation remain poorly understood. In collaboration with the Hurley lab (UC Berkeley) and the Hummer lab (Max Planck Institute), we recently visualized how the PI3K complex is kept inactive and switched on by its pseudokinase subunit, VPS15, upon autophagy induction (Cook*, Chen*, Nguyen*, Cabezudo* et al. Science 2025; *co-first). These findings provide potential avenues for therapeutic targeting of mitophagy and autophagy pathways in neurodegenerative diseases such as PD and ALS.